George C. Lombardi

I'll research this attorney's professional background before drafting.

Let me verify the tracked cases and check firm/rebrand and PTAB details.

George C. Lombardi — Patent Litigation Practice Summary

Focus areas. Lombardi's patent practice is centered on pharmaceutical and life sciences litigation, particularly Hatch-Waxman ANDA cases, and extends to medical devices and instruments, computer and telecommunications technology, and financial-services/software patents. His tracked matters are consistent with that mix: the Otsuka v. Par Pharmaceutical ANDA dispute over generic tolvaptan (SAMSCA®), and the DataTreasury v. Bank of America check-imaging patent litigation. Published practice descriptions (Winston & Strawn/Winston Taylor, IAM Patent 1000, Chambers, WIPR) also credit him with trials involving telephone and computer technology and medical devices. He is characterized by directory sources primarily as a trial lawyer rather than a prosecution or counseling practitioner.

Side preference. He works both sides but tilts toward defense of operating companies. The tracked docket shows two defendant-side appearances (DataTreasury v. Bank of America; one additional matter listed as of counsel) against one plaintiff-side appearance (Otsuka v. Par). That matches his broader record: he has defended generic manufacturers such as Barr/Teva in ANDA suits, while also representing brand owners such as Otsuka and Monsanto as affirmative patent plaintiff.

Firm context. Lombardi has spent his entire career at Winston & Strawn, joining after law school in 1984 and remaining there since; he is a partner in the Chicago office and formerly co-chaired the firm's litigation department and served on its executive committee. Effective June 1, 2026, Winston & Strawn combined with the U.K.-led business of Taylor Wessing to form Winston Taylor, and Lombardi's profile now appears under that name. No prior-firm history was found.

Notable matters. His most prominent result is the 2012 Monsanto v. E.I. duPont de Nemours jury verdict of roughly $1 billion on Roundup Ready® seed technology, reported as the third-largest verdict of 2012 by the National Law Journal and recognized by Law360 with an "IP MVP" award. He also led the defense in Eli Lilly v. Barr Laboratories (Prozac®), which invalidated the patent at issue; represented Teva/Barr in Yasmin® litigation against Bayer; and won a Teva judgment invalidating a Bristol-Myers Squibb compound patent in the Baraclude® ANDA case. Other reported trial wins include Zubsolv®, Temodar®, Razadyne®, and a bench trial victory for Corning in its cell-culturing dispute with Wilson Wolf. In the tracked DataTreasury matter, the asserted Ballard patents were ultimately invalidated through post-grant CBM review at the PTAB (affirmed by the Federal Circuit in a 2016 summary order) — a proceeding brought by the bank defendants, though public sources do not confirm Lombardi's personal role in the PTAB filings. Beyond that, I could not verify from available sources whether he appears regularly in IPR/PGR proceedings in his own name; his documented patent experience is predominantly district court trial work.

Bar and education. Admitted in Illinois (1984); JD, University of Michigan Law School (1984); BA, Dartmouth College (1980).